Lbp Am Sa Takes Position in Elevance Health, Inc. $ELV

Lbp Am Sa purchased a new stake in Elevance Health, Inc. (NYSE:ELV) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 12,061 shares of the company’s stock, valued at approximately $3,897,000.

Several other large investors also recently bought and sold shares of ELV. Nilsine Partners LLC raised its stake in shares of Elevance Health by 1.5% in the 3rd quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after acquiring an additional 29 shares during the period. HBK Sorce Advisory LLC increased its position in Elevance Health by 4.4% during the third quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock worth $260,000 after buying an additional 31 shares during the period. Detalus Advisors LLC raised its stake in shares of Elevance Health by 1.8% during the third quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock worth $558,000 after purchasing an additional 31 shares during the last quarter. Forum Financial Management LP raised its position in Elevance Health by 1.1% in the third quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock worth $960,000 after acquiring an additional 33 shares in the last quarter. Finally, Vermillion & White Wealth Management Group LLC increased its holdings in Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after acquiring an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. TD Cowen restated a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. The Goldman Sachs Group started coverage on Elevance Health in a research note on Tuesday, October 14th. They set a “neutral” rating and a $343.00 price objective for the company. Barclays raised their target price on shares of Elevance Health from $385.00 to $404.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Mizuho set a $413.00 target price on Elevance Health in a research report on Friday, January 9th. Finally, Guggenheim lifted their target price on shares of Elevance Health from $398.00 to $414.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Twelve equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, Elevance Health presently has a consensus rating of “Moderate Buy” and an average price target of $399.63.

Elevance Health Trading Down 14.4%

ELV opened at $322.55 on Wednesday. The stock has a market capitalization of $71.68 billion, a P/E ratio of 13.19, a P/E/G ratio of 1.94 and a beta of 0.51. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75. The firm’s fifty day simple moving average is $350.06 and its 200 day simple moving average is $328.78. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of 0.71.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.07 by $0.26. Elevance Health had a net margin of 2.84% and a return on equity of 16.17%. The business had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.